



**Coventry and  
Warwickshire**  
Integrated Care Board

# Sativex Position Statement Policy

Reference Number:	This will be applied to all new ICB-wide PPSs by the Governance and Corporate Affairs Team and will be retained throughout its life span.
Version:	Version 1.0
Name of responsible Committee and date approved or recommended to Integrated Care Board Board:	Audit Committee
Date approved by the Integrated Care Board (if applicable):	1 July 2022
Next Review Date:	1 April 2024
Expiry Date:	1 October 2024
Name of author and title:	Altaz Dhanani, ICB
Name of reviewer and title:	Angela Brady, Chief Medical Officer, ICB
Department:	Corporate Office

#### VERSION HISTORY

Date	Version	Changes made to previous version	Consulting and Endorsing Stakeholders, Committees / Meetings / Forums etc.

## Coventry & Warwickshire ICB

### Position Statement: THC: CBD oromucosal spray (Sativex®) for Multiple Sclerosis

<b>Treatment</b>	<b>THC: CBD oromucosal spray (Sativex®)</b> to treat moderate to severe spasticity in adults with multiple sclerosis
<b>ICB position</b>	<p>The following outlines the Coventry &amp; Warwickshire Integrated Care Board (ICB) position:</p> <ul style="list-style-type: none"><li>• THC: CBD oromucosal spray for multiple sclerosis (MS) is considered of low priority and hence not recommended for use for people registered with a Coventry or Warwickshire GP or for those residing within Coventry and Warwickshire and not currently registered with any GP</li><li>• Coventry &amp; Warwickshire APC does not recommend this treatment since the available evidence does not support use.</li></ul>
<b>Summary of Evidence</b>	<p>The National Institute for Health and Care Excellence (NICE) has published: Cannabis-based medicinal products: Evidence review for spasticity; NICE guideline NG144<sup>1</sup>: This outlines new and existing trial data for clinical effectiveness; Key points are as follows:</p> <ul style="list-style-type: none"><li>• Studies found an improvement in patient reported spasticity. However, various preparations were used within the studies and indeed, not all studies were in relation to THC: CBD oromucosal spray. In addition, several studies used unlicensed doses, often those above the recommended maximum of 12 sprays daily. The remaining studies were of poor quality and had limitations</li><li>• There was an absence of head-to-head studies comparing THC: CBD oromucosal spray with other treatments. Therefore, there is a lack of evidence suggesting THC: CBD oromucosal spray could be used in place of currently recommended treatments</li><li>• No studies found any significant differences in health-related quality of life (HRQoL) measures</li><li>• No new cost-effective evidence was reviewed by NICE; only two relevant studies were identified and cited from previous NICE reviews. The two cost-utility analyses were described as having 'very serious limitations' and 'potentially serious limitations'<sup>1</sup>.</li></ul>

<b>Cost</b>	The annual cost of THC: CBD oromucosal spray (Sativex®) is £5,100 per patient, assuming a maximum of 12 sprays are administered per day (Drug Tariff September 2021) <sup>2</sup>
<b>Approved date</b>	TBC (Recommended by CEG 21/10/2021): for consideration via Clinical Quality & Governance Committee.
<b>Date for review</b>	TBC
<b>References</b>	<p>1. NICE (2019). Cannabis-based medicinal products: Evidence review for spasticity; NICE guideline NG144. Available at: <a href="https://www.nice.org.uk/guidance/NG144/evidence-review">NG144 Evidence review C (nice.org.uk)</a> Accessed: 21/09/2021.</p> <p>2. NHSBSA (2021) Drug Tariff September 2021. Available at: <a href="https://www.nhs.uk/medicines/nhsbsa/drug-tariff">NHS Electronic Drug Tariff (nhsbsa.nhs.uk)</a> Accessed: 21/09/2021.</p>

Prepared by: Jas Sagoo

Date: October 2021